June 17, 2023

Back in April, the FDA pub­lished draft guid­ance on when and how a phar­ma com­pa­ny can no­ti­fy the agency of an in­ter­rup­tion or halt to

Mer­ck’s Keytru­da notched an­oth­er pos­i­tive set of da­ta, this time in a rare can­cer of the esoph­a­gus that sets up the com­pa­ny to re­ceive full

Biotechs left and right an­nounced stock sales this week af­ter da­ta drops at AS­CO, the Eu­ro­pean Hema­tol­ogy As­so­ci­a­tion’s an­nu­al meet­ing and else­where. The famed genome

Co­herus Bio­Sciences is mak­ing a small stock-for-stock trans­ac­tion to shore up its im­muno-on­col­o­gy pipeline in an ac­qui­si­tion of Sur­face On­col­o­gy that is val­ued at $65

Twist Bio­science is lay­ing off 212 em­ploy­ees, ef­fec­tive Ju­ly 3, ac­cord­ing to Cal­i­for­nia WARN no­tices — with 197 of those staffers in San Fran­cis­co. The

→ Pre­ston Klassen has mapped out his next des­ti­na­tion as pres­i­dent and R&D chief of mi­croR­NA de­vel­op­er Reg­u­lus Ther­a­peu­tics. Klassen was the CEO of Metacrine,

The FDA grant­ed ac­cel­er­at­ed ap­proval to Genen­tech’s CD20xCD3 bis­pe­cif­ic for pa­tients with a cer­tain type of non-Hodgkin’s lym­phoma on Thurs­day night, as the Roche unit

GSK’s blood can­cer drug mo­melo­tinib has tak­en an­oth­er turn on its wind­ing jour­ney, with the FDA de­lay­ing its re­view of the in­ves­ti­ga­tion­al tablet that GSK

Use of video rather than direct laryngoscope led to better rates of successful tracheal intubation on the first attempt for critically ill patients in the